Evidence map›Paper›PMID 39853355›Full record

ArticleAnalytical and bioanalytical chemistry2025

Absolute quantification of amine metabolites in human cerebrospinal fluid via MS1-centric isotopic N,N-dimethyl leucine (iDiLeu) labeling.

Olga Riusech, Ling Hao, Lingjun Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Olga RiusechDepartment of Chemistry, University of Wisconsin, Madison, WI, USA.
Ling HaoDepartment of Chemistry & Biochemistry, University of Maryland, 8051 Regents Dr., College Park, MD, 20742, USA. linghao1@umd.edu.
Lingjun LiDepartment of Chemistry, University of Wisconsin, Madison, WI, USA. lingjun.li@wisc.edu.ORCID http://orcid.org/0000-0003-0056-3869

Funding

Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI SAGER, MARK · 2009 to 2018
$16.2M
TR&D 2 Metabolic Labels for Ultraplexed Protein Quantification p. 453P41GM108538 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI COON, JOSHUA J · 2016 to 2025
$13.1M
Mass Spectrometric Studies of Neuropeptides in FeedingR01DK071801 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2006 to 2026
$6.7M
Creating a region- specific biomolecular atlas of the brain of Alzheimer’s diseaseR01AG078794 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI, Luigi Puglielli · 2022 to 2026
$3.7M
DiLeu-enabled multiplexed quantitation for biomarker discovery and validation in Alzheimer’s diseaseR01AG052324 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2023 to 2026
$2.3M
Acquisition of a High-Field Dual Source FTICR-MS for Pharmaceutical ResearchS10RR029531 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2011 to 2011
$2.1M
Development of Mass Spectrometry Strategies to Decipher Dynamic Lysosomal Dysfunctions in Frontotemporal DementiaR01NS121608 · NINDS · UNIV OF MARYLAND, COLLEGE PARK · PI Ling Hao · 2021 to 2026
$2.0M
Acquisition of a Dual-Source, High-Performance, Ion Mobility, Quadrupole Time-of-Flight Mass Spectrometry System for Biomedical Research at UW-MadisonS10OD028473 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2021 to 2021
$1.3M
Acquisition of a High Resolution High Speed MALDI Mass Spectrometer for Biomedical Research at UW-MadisonS10OD025084 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2018 to 2018
$598k
NCRR NIH HHS S10 RR029531NCRR NIH HHS S10RR029531NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG052324NIA NIH HHS R01AG052324NIA NIH HHS R01 AG078794NIA NIH HHS R01AG078794NIDDK NIH HHS R01 DK071801NIDDK NIH HHS R01DK071801NIGMS NIH HHS P41 GM108538NIGMS NIH HHS P41GM108538NIH HHS S10 OD025084NIH HHS S10 OD028473NIH Office of the Director S10OD025084NIH Office of the Director S10OD028473NINDS NIH HHS R01 NS121608NINDS NIH HHS R01NS121608
6 · The paper itself

Abstract

Quantitative measurement of metabolites is essential to understand biological and disease processes. Absolute quantification by spiking heavy isotope-labeled internal standards and analyzing on mass spectrometry (MS) platform is a key method to determine the concentration of metabolites in biological samples. However, MS-based absolute quantification is often challenged by the commercial availability and high costs of isotope-labeled internal standards. Here, we establish an absolute quantification method for amine metabolites utilizing isotopic N,N-dimethyl leucine (iDiLeu) tagging on the LC-MS/MS platform. Absolute quantification of metabolites with excellent accuracy and precision can be achieved with five-plex iDiLeu labeling without the need of isotope-labeled internal standards. We demonstrated that iDiLeu labeling improved the separation and detection limits of polar metabolites. Particularly, detection limits for glycine, GABA, and serotonin have been improved by more than 20 folds, and valine by more than 2000 folds. With iDiLeu tagging, 87 amine-containing metabolites were identified and quantified in human cerebrospinal fluid (CSF) samples, revealing potential metabolic changes in Alzheimer's disease patients.

Indexed as

AminesIsotope LabelingLeucineTandem Mass SpectrometryAlzheimer DiseaseChromatography, LiquidHumansLimit of DetectionAminesLeucineAbsolute quantificationAlzheimer’s diseaseHuman cerebrospinal fluidIDiLeuMass spectrometryMetabolites

Identifiers

PMID39853355
PMCPMC12052482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.